ERBB2 and breast cancer: Moreover, one of the possible explanations suggested regarding the acquired resistance to HER2-targeted therapies in BC patients was a link between JAM-A, β-catenin, and FOXA1 that triggers HER2-independent tumor proliferation via HER3 activation [80].